AU2001277621A1 - Antiangiogenic bicyclic derivatives - Google Patents

Antiangiogenic bicyclic derivatives

Info

Publication number
AU2001277621A1
AU2001277621A1 AU2001277621A AU7762101A AU2001277621A1 AU 2001277621 A1 AU2001277621 A1 AU 2001277621A1 AU 2001277621 A AU2001277621 A AU 2001277621A AU 7762101 A AU7762101 A AU 7762101A AU 2001277621 A1 AU2001277621 A1 AU 2001277621A1
Authority
AU
Australia
Prior art keywords
antiangiogenic
bicyclic derivatives
bicyclic
derivatives
antiangiogenic bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277621A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001277621A1 publication Critical patent/AU2001277621A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2001277621A 2000-08-09 2001-08-08 Antiangiogenic bicyclic derivatives Abandoned AU2001277621A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00402256 2000-08-09
EP00402256 2000-08-09
PCT/GB2001/003585 WO2002016348A1 (en) 2000-08-09 2001-08-08 Antiangiogenic bicyclic derivatives

Publications (1)

Publication Number Publication Date
AU2001277621A1 true AU2001277621A1 (en) 2002-03-04

Family

ID=8173807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277621A Abandoned AU2001277621A1 (en) 2000-08-09 2001-08-08 Antiangiogenic bicyclic derivatives

Country Status (2)

Country Link
AU (1) AU2001277621A1 (en)
WO (1) WO2002016348A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498335B2 (en) 2000-03-06 2009-03-03 Astrazeneca Ab Method of producing an antiangiogenic or vascular permeability reducing effect
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
AU2003261807B9 (en) 2002-08-30 2007-02-15 Eisai R & D Management Co., Ltd. Azaarene derivatives
ES2309368T3 (en) * 2002-12-02 2008-12-16 F. Hoffmann-La Roche Ag DERIVATIVES OF INDAZOL AS AN ANTAGONIST OF CRF.
SI1625121T1 (en) 2002-12-20 2010-04-30 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06001660A (en) 2003-08-14 2006-04-28 Hoffmann La Roche Gabanergic modulators.
CN100450998C (en) 2003-11-11 2009-01-14 卫材R&D管理有限公司 Urea derivative and process for producing the same
CA2557745A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
JP2007537238A (en) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク Pyrimidine derivatives for the treatment of abnormal cell proliferation
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (en) 2004-05-14 2007-02-13 Pfizer Prod Inc Pyrimidines derivatives for the treatment of abnormal cell growth.
CA2575180A1 (en) 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
WO2006030826A1 (en) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Medicinal composition
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
NL2000291C2 (en) 2005-11-10 2009-02-17 Pfizer Prod Inc 1- (1- (2-ethoxyethyl) -3-ethyl-7- (4-methylpyridin-2-ylamino) -1 H -pyrazole (4,3-d) pyrimidin-5-yl) piperidine-4-carboxylic acid and salts thereof.
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN101443009A (en) 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
CN101511793B (en) 2006-08-28 2011-08-03 卫材R&D管理有限公司 Antitumor agent for undifferentiated gastric cancer
JP5319306B2 (en) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition for treatment of undifferentiated gastric cancer
TWI484960B (en) * 2007-04-16 2015-05-21 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
CN101848895B (en) 2007-11-09 2013-10-23 卫材R&D管理有限公司 Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2217602B1 (en) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
CA2739488A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
WO2010045188A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
CA2757231A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
KR101918909B1 (en) 2010-08-12 2018-11-15 베링거 인겔하임 인터내셔날 게엠베하 6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CA2952857A1 (en) 2014-06-19 2015-12-23 Merial, Inc. Parasiticidal compositions comprising indole derivatives, methods and uses thereof
CN106660964B (en) 2014-08-28 2021-09-03 卫材R&D管理有限公司 High-purity quinoline derivative and process for producing the same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
RU2729936C2 (en) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer agent
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
EP3510032B1 (en) 2016-09-09 2022-07-06 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
CA3091517A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
MX2022001562A (en) 2019-08-06 2022-04-26 Incyte Corp Solid forms of an hpk1 inhibitor.
KR20220064369A (en) 2019-08-14 2022-05-18 인사이트 코포레이션 Imidazolyl Pyridimidinylamine Compounds as CDK2 Inhibitors
CR20220170A (en) 2019-10-11 2022-10-10 Incyte Corp Bicyclic amines as cdk2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU733551B2 (en) * 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
EP1218360B1 (en) * 1999-10-07 2008-05-28 Amgen Inc., Triazine kinase inhibitors
YU54202A (en) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors

Also Published As

Publication number Publication date
WO2002016348A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU2001277621A1 (en) Antiangiogenic bicyclic derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
IL148997A0 (en) Bicyclic imidazo-3-yl-amine derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2002221827A1 (en) Novel lactame-substituted pyrazolopyridine derivatives
AU2001295992A1 (en) Imidazopyridine derivatives
AU2002216028A1 (en) Novel carbamate-substituted pyrazolopyridine derivatives
AU6314900A (en) Biarylurea derivatives
AU6714700A (en) Cyclopropylindole derivatives
HK1047747B (en) Bicyclic imidazo-3-yl-amine derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
IL149010A0 (en) Bicyclic imidazo-5-yl-amine derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU7952800A (en) 2-alkoxybenzene derivatives
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002212263A1 (en) Substituted 5-amino-1-pentene-3-ol derivatives